Testing Experimental Medication in Healthy Subjects

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

The pharmacokinetics of a single dose of pexidartinib will be investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.

Pharmaceutical medication involved
Patients and healthy individuals accepted

Drug - Pexidartinib

Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.

An Open-label, Single-dose Study to Assess the Pharmacokinetics of Pexidartinib in Subjects With Moderate Hepatic Impairment Compared to Healthy Subjects